Nonresponse to Ketamine in Treatment‐Resistant Bipolar Depression
Neuropsychopharmacology Reports · 2025
DOI: 10.1002/npr2.70038 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Neuropsychopharmacology Reports, 2025. Verfasst von Zofia Kachlik und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdańsk, Poland. Hauptthemen laut MEDLINE: Antidepressive Agents, Bipolar Disorder, Depressive Disorder, Treatment-Resistant, Ketamine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gdański Uniwersytet Medyczny.
Themen: Depression
Abstract (Originalsprache)
Objectives
Ketamine is a prototypical rapid‐acting antidepressant for treatment‐resistant bipolar depression (TRBD), yet many patients do not achieve a meaningful response. This study explored features of ketamine nonresponse in TRBD.
Methods
In a post hoc analysis of a naturalistic study, 35 TRBD patients received a four‐week ketamine regimen (intravenous 0.5 mg/kg or oral 2.0/2.5 mg/kg). Response was measured using the Montgomery‐Åsberg Depression Rating Scale, and baseline sociodemographic and clinical features were compared between responders and nonresponders.
Results
Fourteen patients (40%) were nonresponders. They had a higher median number of psychiatric comorbidities (2 vs. 1; p = 0.0366), were more likely to have any psychiatric comorbidity (78.6% vs. 33.3%; p = 0.0153), and had greater prior benzodiazepine use (64.3% vs. 23.8%; p = 0.0332). No significant links emerged between individual comorbidities or baseline suicidality and response.
Conclusion
Ketamine demonstrates a favorable safety and tolerability profile for short time use in TRBD regardless of isolated baseline characteristics, although a more severe comorbidity burden and benzodiazepine use appear to be associated with nonresponse. Trial Registration NCT04226963 and NCT05565352
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdańsk, Poland.
- Department of Algorithms and System Modeling, Gdansk University of Technology, Gdańsk, Poland.
- Laboratory of Translational Oncology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Gdańsk, Poland.
- Center of Biostatistics and Bioinformatics, Medical University of Gdańsk, Gdańsk, Poland.
ORCID-Profile: Zofia Kachlik, Wiesław Jerzy Cubała, Michał Walaszek, Michał Pastuszak, Krzysztof Pastuszak, Aleksander Kwaśny
Förderung
- Gdański Uniwersytet Medyczny
Zitieren
APA
Kachlik, Z., Cubała, W. J., Walaszek, M., Pastuszak, M., Pastuszak, K., & Kwaśny, A. (2025). Nonresponse to Ketamine in Treatment‐Resistant Bipolar Depression. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.70038
Vancouver
Kachlik Z, Cubała WJ, Walaszek M, Pastuszak M, Pastuszak K, Kwaśny A. Nonresponse to Ketamine in Treatment‐Resistant Bipolar Depression. Neuropsychopharmacology Reports. 2025. doi:10.1002/npr2.70038
BibTeX
@article{Kachlik2025,
author = {Kachlik, Zofia and Cubała, Wiesław Jerzy and Walaszek, Michał and Pastuszak, Michał and Pastuszak, Krzysztof and Kwaśny, Aleksander},
title = {Nonresponse to Ketamine in Treatment‐Resistant Bipolar Depression},
journal = {Neuropsychopharmacology Reports},
year = {2025},
doi = {10.1002/npr2.70038}
}
EUVIMED